The American Journal of Medicine
Volume 118, Issue 6 , Pages 618-624 , June 2005

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization

  • Evguenia C. Charles, PharmD

      Affiliations

    • Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado
    • Clinical Assistant Professor, University of Colorado School of Pharmacy, Denver, Colorado
    • ,
  • Kari L. Olson, BSc(Pharm), PharmD

      Affiliations

    • Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado
    • Clinical Assistant Professor, University of Colorado School of Pharmacy, Denver, Colorado
    • Corresponding Author InformationRequests for reprints should be addressed to Kari L. Olson, BSc (Pharm), PharmD, BCPS, Clinical Pharmacy Cardiac Risk Service, 16601 East Centretech Parkway, Aurora, CO 80011
    • ,
  • Brian G. Sandhoff, PharmD

      Affiliations

    • Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado
    • Clinical Assistant Professor, University of Colorado School of Pharmacy, Denver, Colorado
    • ,
  • David L. McClure, MSc

      Affiliations

    • Clinical Research Unit, Kaiser Permanente of Colorado, Denver, Colorado
    • ,
  • John A. Merenich, MD

      Affiliations

    • Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado
    • Clinical Associate Professor of Medicine, University of Colorado Health Sciences Center, Denver, Colorado

References 

  1. Tolman KG . The liver and lovastatin . Am J Cardiol. . 2002;89:1374–1380
  2. Scandinavian Simvastatin Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)) . Lancet . 1994;344:1383–1389
  3. Sacks FM , Pfeffer MA , Lemuel AM , et al.   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med. . 1996;335:1001–1009
  4. Downs JR , Clearfield M , Weis S , et al.   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS . JAMA . 1998;279:1615–1622
  5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . N Engl J Med. . 1998;339:1349–1357
  6. Heart Protection Study Collaborative Group . MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (a randomized placebo-controlled trial) . Lancet . 2002;360:7–22
  7. PhRMA/FDA/AASLD Drug-induced hepatotoxicity white paper post-marketing considerations. Available from: http://www.fda.gov/cder/livertox/ [cited 2004 Apr 29].
  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  9. Dujovne CA . Side effects of statins (hepatitis versus “transaminitis”—myositis versus “CPKitis”) . Am J Cardiol. . 2002;89:1411–1413
  10. Benichou C . Criteria of drug-induced liver disorders. Report of an international consensus meeting . J Hepatol. . 1990;11:272–276
  11. Naranjo CA , Busto U , Sellers EM , et al.   A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther. . 1981;30:239–245
  12. Williams D , Feely J . Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors . Clin Pharmacokinet. . 2002;41:343–370
  13. Newman CB , Palmer G , Silbershatz H , Szarek M . Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients . Am J Cardiol. . 2003;92:670–676
  14. Ballantyne CM , Corsini A , Davidson MH , et al.   Risk of myopathy with statin therapy in high-risk patients . Arch Intern Med. . 2003;163:553–564
  15. Smith CC , Bernstein LI , Davis RB , et al.   Screening for statin-related toxicity . Arch Intern Med. . 2003;163:688–692
  16. Chalasani N , Aljadhey H , Kesterson J , Murray MD . Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity . Gastroenterology . 2004;126:1287–1292
  17. MacDonald JS , Gerson RJ , Kornbrust DJ , et al.   Pre-clinical evaluation of lovastatin . Am J Cardiol. . 1988;62:16J–27J

PII: S0002-9343(05)00094-X

doi: 10.1016/j.amjmed.2005.02.008

The American Journal of Medicine
Volume 118, Issue 6 , Pages 618-624 , June 2005

Article Tools

* Image Usage & Resolution